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Abstract
Background: Overexpression of Aurora-A and mutant Ras (RasV12) together has been detected
in human bladder cancer tissue. However, it is not clear whether this phenomenon is a general
event or not. Although crosstalk between Aurora-A and Ras signaling pathways has been reported,
the role of these two genes acting together in tumorigenesis remains unclear.
Methods: Real-time PCR and sequence analysis were utilized to identify Ha- and Ki-ras mutation
(Gly -> Val). Immunohistochemistry staining was used to measure the level of Aurora-A expression
in bladder and colon cancer specimens. To reveal the effect of overexpression of the above two
genes on cellular responses, mouse NIH3T3 fibroblast derived cell lines over-expressing either
RasV12and wild-type Aurora-A (designated WT) or RasV12 and kinase-inactivated Aurora-A (KD)
were established. MTT and focus formation assays were conducted to measure proliferation rate
and focus formation capability of the cells. Small interfering RNA, pharmacological inhibitors and
dominant negative genes were used to dissect the signaling pathways involved.
Results: Overexpression of wild-type Aurora-A and mutation of RasV12 were detected in human
bladder and colon cancer tissues. Wild-type Aurora-A induces focus formation and aggregation of
the RasV12 transformants. Aurora-A activates Ral A and the phosphorylation of AKT as well as
enhances the phosphorylation of MEK, ERK of WT cells. Finally, the Ras/MEK/ERK signaling
pathway is responsible for Aurora-A induced aggregation of the RasV12 transformants.
Conclusion:  Wild-type-Aurora-A enhances focus formation and aggregation of the RasV12
transformants and the latter occurs through modulating the Ras/MEK/ERK signaling pathway.
Background
The role of Aurora-A, a serine/threonine kinase, in tumor-
igenesis has been reported [1-4]. In proliferative cells, the
expression levels of Aurora-A mRNA and protein are low
during G1 and S phases. The levels peak at G2 phase and
fall during mitotic exit and G1 phase of the next cell cycle
[3,5]. Aurora-A protein consists of 403 amino acids and
has a molecular weight of 46 kilo Daltons (kDa) [5].
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Overexpression of Aurora-A has been detected in several
human cancer cell lines and cancers of the following tis-
sues: bladder, breast, colon, liver, gingival, gliomas,
medulloblastoma, ovarian, pancreas, prostate and tongue
[6-16]. Ectopic expression of Aurora-A in mouse NIH3T3
cells and Rat1 fibroblasts causes centrosome amplifica-
tion and cell transformation [8,17]. This suggests that
Aurora-A gene amplification and overexpression play a
role in human carcinogenesis, largely due to the effect of
Aurora-A on oncogenic cell growth, rather than a loss of
maintenance of centrosomal or chromosomal integrity.
Ras proteins are important for controlling the activities of
several crucial signaling pathways. The ras-gene encoded
proteins become constitutively active due to point muta-
tions in their coding sequences, especially at amino acid
12, 13, and 61 [18]. These activated Ras proteins contrib-
ute significantly to several aspects of the malignant phe-
notype, including deregulation of tumor-cell growth,
programmed cell death, invasiveness, and induction of
new blood-vessel formation [19].
Various Ras-regulated signaling pathways are responsible
for cell survival, transformation, and apoptosis [20,21].
Multiple effectors have been found downstream of Ras,
including Raf, PI3K, RalGDS, RIN1, MEKK, GAP, NF1,
and AF6 [21]. Overexpression of Ha-rasval12 oncogene not
only transforms NIH3T3 cells but also sensitizes them to
various stresses, such as serum depletion, Lovastatin,
tumor necrosis factor-α and 5-FU treatments [22-26].
Through the Ras/Raf interaction, Raf activates MEK1/2,
which subsequently phosphorylates ERK1/2 and activates
the transcription factor, Elk [27,28]. After activation, Elk
complexes with the serum responsive factor (SRF) and
binds to the serum responsive element (SRE) which is an
important element in the c-fos promoter [29-31]. RalGDS,
another Ras effector, associates with Ras and activates Ral
(a small GTPase), including RalA and RalB [32].
Studies on progesterone-induced maturation of Xenopus
oocytes indicate that overexpression of kinase Eg2, a Xeno-
pus member of the Aurora/Ipl1 family, activates the MAP
kinase pathway [33]. This study raises the possibility that
Aurora protein may also transduce cell transformation sig-
nals through the MAPK signaling pathway. In addition,
Aurora-A could associate with NM23-H1, which may
phosphorylates the scaffold kinase repressor of Ras (KSR)
[34-36]. Gigoux et al., (2002) reported that the interaction
between Aurora-A and RasGAP, a negative Ras regulator,
decreased the kinase activity of Aurora-A [37]. Wu et al.,
(2005) found that RalGDS and RalA are downstream sub-
strates of Aurora-A [38]. Tatsuka et al., (2005) showed
that overexpression of Aurora-A potentiated Ha-ras-medi-
ated oncogenic transformation by increasing focus forma-
tion [39]. Furukawa et al., (2006) showed that Aurora-A is
one of the downstream targets of MAPK signaling [40].
These observations imply some degree of crosstalk
between Aurora-A and Ras signaling pathways.
In this study, the collective role of Aurora-A and Ha-ras in
cell aggregation was unraveled. The possible signaling
pathways involved were also investigated.
Methods
Tumor Tissues
The cancer tissues from National Cheng Kung University
Hospital between 2001 and 2004 were eligible for analy-
sis. Consent from the patients was obtained, and the study
was approved by the institutional review board.
Genomic DNA preparation
The tissues were homogenized with a mortar and a pestle
in the presence of liquid nitrogen, followed by phenol/
chloroform extraction. After ethanol precipitation,
genomic DNA was dissolved in TE buffer.
Detection of Ha- and Ki-ras codon 12 mutation
Detection of Ha-ras codon 12 mutation was conducted
using a commercial SNP system (ABI, USA) [41]. Detec-
tion of Ki-ras codon 12 mutation was conducted using a
commercial SNP system following the manufacturer's
instructions [42] (Roche, Germany).
Plasmids
The wild-type and catalytic-inactive mutant Aurora-A
genes were cloned into pEGFPN1 plasmid (pEGFP-
Aurora-A-WT and pEGFP-Aurora-A-KD). The construction
of pHARalAS183A and pHARalS194A was described pre-
viously [38].
Cell lines and culture
The NIH3T3 cell harbors the inducible Ha-rasV12 onco-
gene (pSVlacO ras) designated as 7-4 [22]. The stable cell
lines Vector, WT and KD were derivatives of 7-4 cells con-
taining GFP (pEGFPN1), wild-type GFP-Aurora-A
(pEGFP-Aurora-A- WT) as well as kinase-inactivated GFP-
Aurora-A (pEGFP-Aurora-A-KD), respectively. All the
fibroblast stable cell lines were maintained in Dulbecco's
modified Eagle medium (DMEM; GIBCO, USA) supple-
mented with 10% calf serum (GIBCO) at 37°C in a 5%
CO2 incubator.
Immunohistochemical (IHC) staining
Tissue sections of paraffin embedded specimens on the
slides after deparaffinization and rehydration. Then, the
slides were soaked in 1× PBS for 5 min and immersed in
1.6% H2O2 (in methanol) for 5 min at room temperature
(RT). After rinsing with 1× PBS, the slides were incubated
with boiling citric acid (10 mM) twice for 5 min and the
slides were rinsed with 1× PBS. Then, the specimens wereBMC Cancer 2009, 9:435 http://www.biomedcentral.com/1471-2407/9/435
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incubated with primary antibody at 4°C for overnight.
On the second day, the slides were rinsed 3 times for 5
min with 1XPBS. Then, the slides were incubated with
biotinylated secondary antibody (DakoCytomation,
LSAB2 System-HRP, USA) for 10 min at RT. After rinsing
the slides 3 times for 5 min with 1× PBS Streptavidin rea-
gent (DakoCytomation) was applied to cover the speci-
mens for 10 min at RT. The slides were rinsed again 3
times for 5 min with 1× PBS. AEC solution (DakoCytoma-
tion) was added to cover specimens for 10 min at RT. The
specimens were rinsed gently with distilled water and
counter stained with 10% hematoxylin. Finally, the slides
were rinsed gently with distilled water and mounted.
Establishment of stable cell lines
After seeding cells on the culture plate for overnight, the
medium was replaced with fresh medium. The desired
plasmid DNA precipitated with ethanol was resuspended
with 40 μl of sterile H2O. Then, 0.5 ml of CaCl2 (pH 7.9)
solution was mixed with the DNA solution, transferred
into a 3 ml tube and mixed with 0.5 ml of HEPES buffer
(pH 7.1). The calcium-DNA solution was transferred into
the cell culture plate and the cells were further incubated
at 37°C in a humidified incubator with 5% CO2. Six
hours after incubation, the medium was replaced with
medium containing serum and incubated for another 24
hr. The cells were then treated with the antibiotic G418
(Sigma, USA) to select for drug-resistant cell lines. Within
10 to 14 days, the cells containing the antibiotic resistance
gene formed colonies, which were selected, propagated
and analyzed for transgene expression by Western blot-
ting.
Cell growth assay
Cell growth was determined by MTT assay. The cells (1 ×
103/well) were plated in 96-well plates. After incubation
with or without IPTG (2.5 mM) for the indicated times,
the cells were treated with 10 μl of MTT solution (5 mg/
ml, Sigma, USA) and incubated for another 3 h at 37°C.
Finally, 100 μl DMSO were added to lyses the cells, the
absorbance of the cell lysates was measured at 540 nm by
a Dynatech Mr 5000 microplate reader (Dynatech labora-
tories, USA).
Focus formation assay
The cells (5 × 102) were plated on 10 cm plates with or
without IPTG (2.5 mM). Media with or without IPTG were
changed every 3-4 days for 2 weeks. The cells were washed
twice, and then fixed with 4% paraformaldehyde for 10
min at 37°C. The paraformaldehyde was then aspirated
from the plates, and washed twice with 1× PBS. Giemsa
solution (Sigma, USA) was added to cover the bottom of
the plate. After incubation at RT for 5 min, Giemsa solu-
tion was poured off, and the plates were rinsed in double
distilled H20 until excess color ceased coming off. The
plates were dried at RT and the foci were counted.
RalA pull-down assay
The cells were lysed in lysis buffer (50 mM Tris-HCl, pH
7.4, 5 mM MgCl2, 1% Nonidet P-40, 150 mM NaCl, 1 mM
phenylmethylsulfonyl fluoride). Total cell lysates (500
μg) were incubated for 1 h at 4°C with 50 μl of glutath-
ione beads (Sigma, USA) coated with GST-RalBD that had
been produced in Escherichia coli. Then, the beads were
washed three times with lysis buffer and boiled in the
sample buffer. Samples were resolved on a 12% SDS-
PAGE, followed by Western blot analysis using anti-RalA
antibody [43,44].
Western blot analysis
Cell lysates (50 μg) were subjected to 12% SDS-PAGE and
subsequently transferred to a PVDF membrane (Millipore,
USA). The membranes were blocked with 5% non-fat
milk for 1 h at RT. The membranes were washed with anti-
Aurora-A (Transduction, BD, Germany), anti-AKT (Cell
signaling technology), anti-p-AKT(Thr308) (Cell signal-
ing technology), anti-Ras (Oncogene, USA), anti-p-
MEK(Ser217/221) (Cell Signaling technology, USA), anti-
ERK1/2 (Cell Signaling technology), anti-p-ERK1/2
(Thr202/Tyr204) (Cell signaling technology), anti-p-
H3S10 (Cell signaling technology), and anti-β-actin
(Sigma) antibodies. The reaction was followed by probing
with peroxidase-coupled secondary antibodies and then
detected by enhanced chemiluminescence (Amersham
Pharmacia, USA).
Statistical Analysis
Densitometry data were represented as fold increase. Stu-
dent's t test was used to analyze the comparisons of differ-
ences, and p = 0.01 was considered significant.
Results
Detection of Aurora-A overexpression accompanied with 
Ha-ras mutation in bladder cancers
Aurora-A overexpression accompanied with Ha-ras codon
12 mutation has been reported in bladder cancers [41]. In
this study, Ha-rasV12 mutation was detected in the tumour
part of the bladder cancer specimen by SNP-real-time PCR
and verified by sequence analysis (Figure 1A, Gly12 -> Val
12). The Aurora-A protein overexpression was detected in
the same cancer part of the bladder tissue compared to the
normal part by IHC staining (Figure 1B, T vs. N). Simi-
larly, Ki-ras  codon 12 mutation and higher expression
level of Aurora-A were only detected in the cancer part of
the colon tissue (Figure 1C and 1D). Taken together,
despite of the difference in transformation of NIH3T3
cells by Ki-ras and Ha-ras, overexpression of Aurora-A and
RasV12 (Ki- or Ha-) mutations are simultaneously detected
in various cancers including bladder and colon.BMC Cancer 2009, 9:435 http://www.biomedcentral.com/1471-2407/9/435
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Detection of Ha- and Ki-RasG12V mutation and overexpression of Aurora-A in bladder and colon cancer specimens Figure 1
Detection of Ha- and Ki-RasG12V mutation and overexpression of Aurora-A in bladder and colon cancer spec-
imens. (A) Sequence analysisof Ha-ras codon 12 mutations of bladder cancer specimen shows the Gly12 to Val12 mutation of 
Ha-ras gene. (B) Aurora-A protein expression in bladder cancer (T) and normal tissue (N) was detected by IHC staining using 
anti-Aurora-A specific antibody. (C) Sequence analysisof Ki-ras codon 12 mutations of colon cancer specimen shows the Gly12 
to Val12 mutation of Ki-ras gene. (D) Aurora-A protein expression in colon cancer (T) and normal tissue (N). " * " indicates 
the mutation site of ras gene. The pink arrow points the expression of Aurora-A by IHC stain.
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Establishment of stable cell lines over-expressing Aurora-A 
and mutant RasV12
It is intriguing to unravel the combined effects of Aurora-
A and mutant RasV12 on the morphological change and
tumorigenesis of the cells. Stable cell lines were estab-
lished by transfecting Vector DNA, wild-type Aurora-A or
kinase-inactivated Aurora-A into 7-4 cells, which was
derived from NIH/3T3 cells harboring the inducible Ha-
rasV12 oncogene [23], designated Vector, WT and KD cell
line, respectively. The expression levels of Ha-rasV12 in
Vector, WT and KD cells in the presence of IPTG were
much higher compared to the cells without IPTG (Figure
2A). Aurora-A can physically interact with the tail of His-
tone H3 (H3) and efficiently phosphorylates H3 at
serine10 [45-48]. In addition, activation of ERK pathway
in Ha-ras  transformed mouse fibroblasts increases the
level of p-H3S10. Consistently, our data showed the level
of phosphorylated H3S10 (p-H3S10 detected by anti-p-
H3S10 antibody) in WT cells (Figure 2A, lane 2, 1.8 fold)
was higher than in Vector cells (Figure 2A, lane 1, 1.0 fold)
and KD cells (Figure 2A, lane 3, 0.9 fold) in the absent of
IPTG where Ras was not overexpressed. Our data showed
that the Aurora-A overexpressed in WT cells is functional.
In the presence of IPTG, where RasV12 protein was overex-
pressed, the level of phosphorylated H3S10 was increased
both in Vector (Figure 2A, lane 4, 2.8 fold), WT (Figure
2A, lane 5, 3.8 fold) and KD (Figure 2A, lane 6, 2.8 fold)
cells.
Biological activity analysis showed that WT cells over-
expressing wild-type Aurora-A became rounded and
formed aggregates in the presence of IPTG compared to
the Vector cells and KD cells (Figure 2B). Transforming
analysis showed that WT cells form more foci compared
to Vector and KD cells (Figure 2C). Despite the fact that
focus numbers were also increased in the other two cell
lines, a further increase of focus number in WT cells was
observed after IPTG induction (Figure 2C). Taken
together, both Aurora-A and mutant RasV12 overexpres-
sion can induce focus formation. Further induction of
focus formation was detected when these two genes were
overexpressed simultaneously.
Cell proliferation analysis showed that WT cells grew
slower than Vector and KD cells in the absence of IPTG.
Growth rate of Vector, WT and KD cells were decreased
when mutant Ras was overexpressed (Fig. 2D). The
increase of cell aggregation of WT cells in the presence of
IPTG was independent of cell growth rate.
Aurora-A overexpression increases phosphorylation status 
of MEK/ERK and AKT as well as the activity of RalA in the 
RasV12 transformants
To clarify the effects of Aurora-A on the signaling path-
ways related to Ras overexpression, three downstream sig-
naling pathways of Ras, Raf/MEK, PI3K/AKT and RalGDS/
Ral A were investigated. The phosphorylation of MEK (p-
MEK) was higher in WT cells (Figure 3A, lane 2, 1.7 fold)
than that in Vector (Figure 3A, lane 1, 1.0 fold) and KD
cells (Figure 3A, lane 3, 0.8 fold). P-MEK levels in each cell
line were further increased after IPTG induction (RasV12 is
over-expressed) (Figure 3A, lane 4, 5, and 6). The same
phenomenon was also been observed in p-ERK1/2 (Figure
3A). These results indicated that Aurora-A may further
increase Ras induced MEK/ERK phosphorylation.
The effect of Aurora-A on the PI3K/AKT pathway was eval-
uated by detecting phosphorylation of AKT (p-AKT). The
p-AKT level was also higher in WT cells (Figure 3A, lane 2,
2.1 fold) compared to Vector and KD cells (Figure 3A, lane
1, 1.0 fold and lane 3, 1.1 fold, respectively). Upon IPTG
induction, RasV12 overexpression increased the level of p-
AKT in Vector and KD cells (Figure 3A, lane 4, 1.8 fold and
lane 6, 2.1 fold, respectively). Co-expression of RasV12 and
wild-type Aurora-A in WT cells increases the level of p-AKT
(Figure 3A, lane 5, 3.5 fold) as compared to
RasV12overexpression alone (Figure 3A, lane 4, 1.8 fold).
The RalGDS/RalA signaling pathway was determined by
detecting the activity of RalA using GST-RalBD pull-down
assay. As shown in Figure 3A, Aurora-A overexpression
alone activated RalA (Figure 3A, lane 2, 2.0 fold) as com-
pared to the parental Vector cells (Figure 3A, lane 1, 1.0
fold). After IPTG induction, The RalA activity was
increased by RasV12 overexpression (Figure 3A, lane 4, 2.5
fold). Co-expression of RasV12 and wild-type Aurora-A in
WT cells increase the activity of RalA of RasV12 (Figure 3A,
lane 5, 3.7 fold). Taken together, both Aurora-A and
RasV12 increased the levels of p-MEK, pERK1/2, and p-AKT
and the activation of RalA. This induction was further
enhanced when Aurora-A and RasV12 were overexpressed
simultaneously.
To further confirm our results, Aurora-A specific small
interference RNA (siRNA) was used. As shown in Figure
3B, Aurora-A specific siRNA decreased the expression level
of Aurora-A in WT cells. Accordingly, levels of p-MEK/p-
ERK, p-AKT and activation of RalA were also decreased
when Aurora-A siRNA was introduced into WT cells upon
IPTG induction. Our results confirmed that wild-type-
Aurora-A enhance Ras downstream signaling pathways
including MEK/ERK, AKT and RalA.
The MEK/ERK pathway is involved in WT cell aggregation
The involvement of MEK/ERK, PI3K/AKT and RalGDS/
RalA signaling pathways in Aurora-A-related cell aggrega-
tion (Fig. 2B, WT + IPTG) was clarified by treatment of the
cells with the following inhibitors: FTI-277, a farnesyla-
tion inhibitor of Ras; PD-98059, the inhibitor of MEK
kinase and LY-294002, the inhibitor of PI3K kinase andBMC Cancer 2009, 9:435 http://www.biomedcentral.com/1471-2407/9/435
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Stable overexpression of wild-type or kinase-dead Aurora-A in WT and KD cells Figure 2
Stable overexpression of wild-type or kinase-dead Aurora-A in WT and KD cells. (A) Expression levels of human 
Aurora-A protein (wild-type: WT; kinase-inactivated: KD) and Ras in the Vector, WT and KD cells were detected by western 
blot analysis using anti-Aurora-A and anti-Ras specific antibodies. β-actin was used as the equal loading control. The levels of p-
H3S10 protein were quantified by a densitometer. The expression level of p-H3S10 in Vector cells without IPTG induction was 
set as 1.0 fold. (B) Morphology of Vector, WT and KD cells with or without IPTG induction. (C) Upper panel: Cells (5 × 102) 
were grown in 10 cm culture dishes with or without IPTG inductionfor two weeks. The foci were stained using Giemsa stain. 
Lower panel: Quantitative foci numbers of Vector, WT and KD cells with or without IPTG induction. (D) Growth curve of cell 
lines was measured daily for 5 days using MTT assay. The experiments were conducted in triplicate and repeated three times.
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Wild-type Aurora-A increases phosphorylation of MEK/ERK, AKT and the activity of RalA of RasV12 transformants Figure 3
Wild-type Aurora-A increases phosphorylation of MEK/ERK, AKT and the activity of RalA of RasV12 transform-
ants. (A) The phosphorylation of MEK was detected by anti-p-MEK antibody. The expression levels of AKT and p-AKT were 
detected using anti-AKT and anti-p-AKT specific antibodies.Ral A activity was detected by Ral pull-down assay. The expression 
level of each protein in three cells was shown graphically at the bottom panel. (B) After Aurora-A siRNA (5 μg) was trans-
fected into WT cells for 6 h, IPTG was added and incubated for another 48 h. The total cell lysates (100 μg) were separated by 
12% SDS-PAGE. Ral A, Ras, Aurora-A and β-actin were detected using Western blotting. The level of each protein was quanti-
fied by a densitometer. The expression level of each protein in Vector cells without IPTG induction was set as 1.0 fold. " * ": p 
 0.01
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RalASa94A, a mutant of Ral. FTI-277 restrains Ras protein
as a non-farnesylated form and inhibits p-ERK1/2 expres-
sion dose-dependently but had no effect on p-AKT (Figure
4A, lanes 2 and 3). PD-98059 decreased the phosphoryla-
tion of ERK1/2 (p-ERK1/2) but had no effect on other sig-
naling pathways (Figure 4A, lanes 4 and 5). LY-294002
reduced the phosphorylation of AKT (p-AKT) but had no
effect on another signaling pathway (Figure 4A, lanes 6
and 7). In summary, in WT cells Aurora-A increases the
expression of p-ERK1/2 in a Ras dependent manner. How-
ever, FTI-277 does not reduce the p-AKT in WT cells co-
expressing RasV12  and wild-type Aurora-A. Wild-type
Aurora-A activates RalA (Figure 3A and 3B) and phospho-
rylates RalA at serine194 to promote cellular transforma-
tion and migration [38]. To reveal the role of RalA
phosphorylation at ser194 in Aurora-A induced RalA acti-
vation in WT cells, the mutants RalAS183A or RalAS194A
were transiently transfected into WT cells and the RalA
activity was evaluated. Consistent with a previous report
[38], only RalAS194A could reduce the Ral A activity (Fig-
ure 4B, lane 3).
To determine which signaling pathway is involved in the
aggregation of WT cells during RasV12 overexpression, we
first demonstrated that Aurora-A induced cell aggregation
was blocked by Aurora-A specific small interfering RNA
(Figure 4C). The WT cells were treated with FTI-277, PD-
98059 or LY-294002 for 24 h and cell aggregation was
observed. Both FTI-277 and PD98059 reversed the aggre-
gation of WT cells, whereas LY-294002 showed no effect
on cell aggregation (Figure 4C). Because mutant
RalAS194A was unable to block cell aggregation, its role in
Aurora-A induced cell aggregation was excluded (Figure
4C). Taken together, the Ras/MEK/ERK signaling pathway
but not the PI3K/AKT or RalGDS/RalA pathway is respon-
sible for Aurora-A induced cell aggregation.
Discussion
Overexpression of an oncogene such as ras  may cause
senescence of transformed cells, and this event can be
reversed by overexpression of a second oncogene such as
c-myc, and Twst1/2 [49,50]. Aurora-A can promote the cell
transformation of Ha-ras transformed BALB/c 3T3 A31-1-
1 cells [39]. The nuclear EGFR induced by EGF associates
with Stat5 to bind and increase Aurora-A gene expression,
which ultimately leads to chromosome instability and
tumorigenesis [51]. We previously reported that onco-
genic Ras-induced morphological changes (from spindle-
shaped to round) occur through the MEK/ERK signaling
pathway to down-regulate Stat3 at a posttranslational
level in NIH3T3 cells. Microtubule disruption is involved
in the morphologic changes, which can be reversed by
overexpression of Stat3 [52]. In this study, we determine
that overexpression of wild-type-Aurora-A can enhance
Ha-rasV12 transformant aggregation through the MEK/ERK
signaling pathway.
The effector domain mutant of oncogenic Ras, RasV12S35,
which specifically activates the Raf/MEK/ERK pathway in
transformed NIH3T3 cells, can induce subcutaneous
tumor formation and lung metastases. In these RasV12S35-
transformed NIH 3T3 cells, high levels of activated ERK1/
2 were detected. By contrast, the cells derived from the
other effector domain mutants, RasV12G37  (PI3K) or
RasV12C40 (RalGDS), did not show changes at the level of
ERK1/2 activation and tumor metastasis [53]. The
increase of ERK1/2 activation could lead to enhanced
expression of many proteolysis enzymes such as the
matrix metalloprotease (MMP) family genes which can
degrade extracellular matrix, leading to increased cell
invasiveness [54,55]. Furthermore, Aurora-A-regulated
epithelial-mesenchymal transition and invasion are medi-
ated by mitogen-activated protein kinase (MAPK) phos-
phorylation [58]. Our current and previous studies reveal
that RasV12 mutation and Aurora-A overexpression can be
detected simultaneously in human bladder and colon
cancers (Figure 1). Co-expression of wild-type Aurora-A
and mutant Ras enhances the signaling of the MEK/ERK,
AKT and RalA activity (Figure 3). I
The activation of ERK1/2 requires phosphorylation of the
conserved tyrosine and threonine residues by dual specific
MAPK kinases (MEK), which are activated by the serine/
threonine kinase Raf through phosphorylation. Scaffold-
ing proteins such as MEK partner (MPI) or kinase suppres-
sor of Ras (KSR) enhance the MEK/ERK signaling pathway
in response to different stimuli [36,56-66]. The KSR/MEK
complex is recruited to the membrane following dephos-
phorylation by phosphatase 2A (PP2A) at the Ser392 res-
idue leading to release 14-3-3 from KSR and then exposes
the C1 domain, which is required for the membrane local-
ization of KSR, as well as the FxFP MAPK binding site. At
the membrane, Raf-1 is activated and KSR provides a plat-
form for the phosphorylation/activation of associated
MEK and ERK [62,65]. Other proteins might help recruit
activated Raf, triggering MEK phosphorylation. PP2A also
interacts with Aurora-A [67]. Whether the PP2A may reg-
ulate Aurora-A and KSR complex to affect the MEK/ERK
signaling pathway is valuable to explore. In addition,
Aurora-A interacts with the other tumor suppressor
RASSF1A. Aurora-A phosphorylates RASSF1A at
Threonine202 and/or Serine203. Knockdown of RASSF1A
reduces Aurora-A activation; however, the recombinant
RASSF1A can not activate recombinant Aurora-A in vitro
suggesting that RASSF1A may function as a scaffold for
Aurora-A activation [68,69]. The possibility of the interac-
tion between Aurora-A and KSR or RASSF1A requires
more investigation and the involvement of other uniden-
tified factor(s) in ERK1/2 activation induced by Aurora-A
in RasV12 transformants can not be excluded.
PI3K/AKT is a down stream signaling pathway of Ras. In
Figure 3A, RasV12 or Wild-type Aurora-A alone increasesBMC Cancer 2009, 9:435 http://www.biomedcentral.com/1471-2407/9/435
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The MEK/ERK pathway is involved in the aggregation of WT cells Figure 4
The MEK/ERK pathway is involved in the aggregation of WT cells. (A) Cells(5 × 105) were seeded in 60 mm plates. 
After IPTG induction for 24 h, the signaling pathway inhibitors were added and incubated for another 24 h. The p-ERK, ERK, p-
AKT, AKT, Ras, Aurora-A and β-actin were detected by western blotting. The level of each protein was quantified by a densi-
tometer. The expression level of each protein in Vector cells without IPTG induction was set as 1.0 fold. (B) Cells(5 × 105) 
were seeded in 60 mm plates.After transfection of WT cells for 6 h with pHA-Vector (5 μg), pHA-RalA183A (5 μg) or pHA-
RalA194A (5 μg), IPTG was added and incubated for another 48 h. The total cell lysates (500 μg) were used to detect the activ-
ity of Ral A by Ral A pull-down assay. (C) Cells (5 × 105) were seeded in 60 mm plates. After IPTG induction for 24 h, the 
inhibitors were added and incubated for another 24 h. For Aurora-A RNAi and RalAS194A, after transfection of cells for 6 h 
with Aurora-A siRNA (5 μg) or pHA-RalA194A (5 μg), IPTG was added and incubated for another 48 h. a.WT cells treated 
with IPTG. b.WT cells treated with IPTG/Aurora-A siRNA c.WT cells treated with IPTG/FTI-277 d.WT cells treated with 
IPTG/PD98059 e.WT cells treated with IPTG/LY294002 f.WT cells treated with IPTG/pHA-RalA194A. FTI-277, a farnesylation 
inhibitor of Ras; PD98059, an inhibitor of MEK kinase; LY294002, an inhibitor of PI3K kinase.BMC Cancer 2009, 9:435 http://www.biomedcentral.com/1471-2407/9/435
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the p-AKT level (Figure 3A, lane 2 and 4) and further
increase p-AKT while both of the genes were overex-
pressed (Figure 3A, lane 5). However, upon FTI-277 treat-
ment, the p-AKT level was not reduced in WT cell when
RasV12 was overexpressed (Figure 4A, lane 2 and 3).
Above results suggest that RasV12 and wild-type Aurora-A
may share a redundant pathway to increase p-AKT expres-
sion level. Nonetheless, the underlying mechanism is
unclear.
Overexpression of Aurora-A induces cell motility of
MDCK cells, mediated by RalA activation through phos-
phorylation of the serine 194 residue of RalA [38]. In the
present study, we demonstrated that overexpression of
either Aurora-A or mutant Ras stimulates RalA activation
and maximal RalA activation is observed when both of the
oncogenes are overexpressed (Fig. 3A, lane 5). However,
we found that the RalAS194A mutant could not block cell
aggregation induced by Aurora-A in the Ha-rasV12 trans-
formants indicating that different signaling pathways may
be transduced to control motility and aggregation of the
different cells.
In summary, our data demonstrate that aberrant Aurora-A
expression plus ras mutation may occur simultaneously in
various cancers, and the increase of MEK/ERK activation
triggered by over-expression of the two oncogenes induces
cell aggregation. We speculate that this event may play a
pivotal role in Ras or Aurora-A related tumor progression.
Conclusions
Taken together, both Aurora-A and RasV12 mutant can acti-
vate the MEK/ERK1/2 signaling pathway. Our study
reveals that additional activation of ERK1/2 may induce
cell aggregation and increase cell focus formation when
both oncogenes are overexpressed together. The results
suggest that increased risk of tumor progression is possi-
ble through increase of ERK1/2 phosphorylation by
diverse oncogenes.
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